Letermovir
- Generic Name
- Letermovir
- Brand Names
- Prevymis
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F4N4O4
- CAS Number
- 917389-32-3
- Unique Ingredient Identifier
- 1H09Y5WO1F
- Background
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis.
- Indication
Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in adult kidney transplant recipients who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegative).
- Associated Conditions
- Cytomegalovirus (CMV) Infections
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06920251
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 36
- Registration Number
- NCT06626555
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06575374
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
- Conditions
- CMVAllogeneic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 50
- Registration Number
- NCT06453460
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, United States
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06449586
- Locations
- 🇨🇳
Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Wuhan, Hubei, China
🇨🇳Ruijin Hospital of Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳The First Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06441669
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
- Conditions
- Pancreas TransplantCytomegalovirus InfectionsKidney Transplant Infection
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 90
- Registration Number
- NCT06407232
- Locations
- 🇺🇸
UW Hospital and Clinics, Madison, Wisconsin, United States
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
- Conditions
- CMV Infection
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Hospital do Rim e Hipertensão
- Target Recruit Count
- 100
- Registration Number
- NCT06341686
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
- Conditions
- Cytomegalovirus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 80
- Registration Number
- NCT06334497
- Locations
- 🇫🇷
Hôpital Necker Enfants Malades, Paris, France
Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT
- Conditions
- Letemovir for the Prevention of CMV Infection After Allo-HSCT
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Cao Weijie
- Target Recruit Count
- 150
- Registration Number
- NCT06306989
- Locations
- 🇨🇳
Cao, Weijie, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.